SABCS 2022 preview – now Arvinas’s degrader takes a knock
As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.
Astra beats Roche twice in a day
Two Astrazeneca breast cancer projects record apparent pivotal successes in settings where Roche had failed.
Close encounters of the Serd kind
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
Roche has a rare breast cancer setback
Giredestrant fails, but the group hopes for better luck in earlier therapy lines.
No Ameera glory for Sanofi
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
SABCS 2021 – Mutant benefit makes Emerald sparkle
Trial design comes into focus as late-stage readouts loom for Sanofi, Roche and Astrazeneca.
